12-132643881-C-T
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4_StrongBP6
The NM_006231.4(POLE):c.4246G>A(p.Ala1416Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000133 in 1,614,154 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_006231.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POLE | NM_006231.4 | c.4246G>A | p.Ala1416Thr | missense_variant | 33/49 | ENST00000320574.10 | NP_006222.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POLE | ENST00000320574.10 | c.4246G>A | p.Ala1416Thr | missense_variant | 33/49 | 1 | NM_006231.4 | ENSP00000322570.5 |
Frequencies
GnomAD3 genomes AF: 0.000302 AC: 46AN: 152168Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000243 AC: 61AN: 251414Hom.: 0 AF XY: 0.000221 AC XY: 30AN XY: 135894
GnomAD4 exome AF: 0.000112 AC: 164AN: 1461868Hom.: 0 Cov.: 32 AF XY: 0.000113 AC XY: 82AN XY: 727234
GnomAD4 genome AF: 0.000335 AC: 51AN: 152286Hom.: 1 Cov.: 33 AF XY: 0.000389 AC XY: 29AN XY: 74468
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:2
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The POLE p.Ala1416Thr variant was not reported in the literature nor was it identified in the following databases: Cosmic or LOVD 3.0. The variant was identified in dbSNP (ID: rs146711942) and ClinVar (classified as uncertain significance by GeneDx, Invitae, Quest Diagnostics Nichols Institute San Juan Capistrano and Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago, and as likely benign by Ambry Genetics). The variant was identified in control databases in 71 of 268310 chromosomes at a frequency of 0.0002646 (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: Ashkenazi Jewish in 41 of 9856 chromosomes (freq: 0.00416), African in 20 of 23610 chromosomes (freq: 0.000847), Other in 4 of 6702 chromosomes (freq: 0.000597), East Asian in 1 of 19250 chromosomes (freq: 0.000052) and European (non-Finnish) in 5 of 118166 chromosomes (freq: 0.000042), but was not observed in the Latino, European (Finnish), or South Asian populations. The p.Ala1416 residue is not conserved in mammals and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 28, 2021 | This variant is associated with the following publications: (PMID: 28873162) - |
Hereditary cancer-predisposing syndrome Benign:2
Likely benign, criteria provided, single submitter | curation | Sema4, Sema4 | Jun 19, 2021 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 11, 2021 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | May 13, 2017 | - - |
Facial dysmorphism-immunodeficiency-livedo-short stature syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago | Sep 12, 2018 | POLE NM_006231.3 exon 33 p.Ala1416Thr (c.4246G>A): This variant has been reported in the literature in at least 1 individual with unspecified advanced cancer (Mandelker 2017 PMID:28873162). This variant is present in 0.4% (47/10152) of Ashkenazi Jewish alleles in the Genome Aggregation Database (http://gnomad.broadinstitute.org/variant/12-133220467-C-T) and is present in ClinVar (Variation ID:240508). This variant amnio acid Threonine (Thr) is present in >40 species, including mammals. This suggests that this variant may not impact the protein. Additional computational prediction tools also do not suggest an impact. In summary, data on this variant is insufficient for disease classification. Therefore, the clinical significance of this variant is uncertain. - |
Colorectal cancer, susceptibility to, 12;C3554576:Facial dysmorphism-immunodeficiency-livedo-short stature syndrome;C5193036:Intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, genital anomalies, and immunodeficiency Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Genomics, Ann and Robert H. Lurie Children's Hospital of Chicago | Mar 30, 2021 | POLE NM_006231.3 exon 33 p.Ala1416Thr (c.4246G>A): This variant has been reported in the literature in at least 1 individual with unspecified advanced cancer (Mandelker 2017 PMID:28873162). This variant is present in 0.4% (47/10152) of Ashkenazi Jewish alleles in the Genome Aggregation Database (http://gnomad.broadinstitute.org/variant/12-133220467-C-T) and is present in ClinVar (Variation ID:240508). This variant amnio acid Threonine (Thr) is present in >40 species, including mammals. This suggests that this variant may not impact the protein. Additional computational prediction tools also do not suggest an impact. In summary, data on this variant is insufficient for disease classification. Therefore, the clinical significance of this variant is uncertain. - |
POLE-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jun 07, 2019 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at